FILING ANALYSIS · FRIDAY, NOVEMBER 13
Evofem Biosciences, Inc. EVFM — 8-K: Results of Operations and Financial Condition
neutral
Evofem Biosciences reported a net income of $0.9 million and generated $0.7 million of operating income in Q3 2026, but net sales decreased to $4.6 million due to lower ex-factory sales for PHEXX. The company remains confident in the long-term value of its products, but lacks dedicated growth capital for brand promotion and physician outreach.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →